Charles River EVP gets 5,257-share stock grant

Charles River Laboratories executive Joseph W. LaPlume reported equity compensation activity involving company common stock.

Rhea-AI Filing Summary

Charles River Laboratories executive Joseph W. LaPlume reported equity compensation activity involving company common stock. On May 29, he received a grant of 5,257 shares of Common Stock, increasing his direct holdings. The filing shows this as a grant or award, not an open-market purchase.

On May 30 and May 31, a total of 979 shares were disposed of at $180.71 per share to satisfy tax withholding obligations related to the award. These tax-withholding dispositions are not open-market sales. After these transactions, LaPlume directly holds 31,298 shares of Common Stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider LaPlume Joseph W

Role EVP, Corp Strategy & Develop

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	235	$180.71	$42K
Exercise Price or Tax Liability	Common Stock	744	$180.71	$134K
Grant/Award	Common Stock	5,257	$180.71	$950K

Holdings After Transaction: Common Stock — 31,298 shares (Direct)

Footnotes (1)

1. F1. Unvested restricted stock units annually ratably vest on: May 29, 2027; May 29, 2028; May 29, 2029; May 29, 2030.

Key Figures

Stock grant: 5,257 shares Tax-withholding shares: 979 shares Tax-withholding price: $180.71 per share +3 more

6 metrics

Stock grant 5,257 shares Common Stock grant/award on May 29

Tax-withholding shares 979 shares Shares delivered for tax liability on May 30–31

Tax-withholding price $180.71 per share Price used for tax-withholding dispositions

Shares after transactions 31,298 shares Directly owned following May 31 transaction

Tax-withholding on May 30 744 shares Disposition to cover tax liability

Tax-withholding on May 31 235 shares Disposition to cover tax liability

Key Terms

grant/award acquisition, tax-withholding disposition, restricted stock units

3 terms

grant/award acquisition financial

"the filing shows this as a grant or award, not an open-market purchase"

tax-withholding disposition financial

"a total of 979 shares were disposed of to satisfy tax withholding obligations"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

restricted stock units financial

"Unvested restricted stock units annually ratably vest on: May 29, 2027; May 29, 2028; May 29, 2029; May 29, 2030."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRL executive Joseph W. LaPlume report in this Form 4 filing?

Joseph W. LaPlume reported an equity award and related tax withholding. He received 5,257 shares of Charles River Laboratories common stock as a grant, with 979 shares disposed of to cover tax obligations, leaving him with 31,298 shares held directly.

How many Charles River Laboratories (CRL) shares did LaPlume receive as an award?

LaPlume received a grant of 5,257 CRL common shares. The Form 4 identifies this as a grant or award acquisition, reflecting executive compensation rather than an open-market purchase, and it increased his directly held share balance before subsequent tax-withholding dispositions.

Why were some of Joseph W. LaPlume’s CRL shares disposed of in this filing?

The disposed CRL shares were withheld for tax obligations. Two transactions on May 30 and May 31 show a total of 979 shares delivered at $180.71 per share to satisfy tax liability, classified as tax-withholding dispositions, not discretionary open-market sales.

What is Joseph W. LaPlume’s CRL share ownership after these transactions?

After the reported transactions, LaPlume directly holds 31,298 CRL shares. This figure reflects the net position following the 5,257-share grant of common stock and the 979 shares disposed of to cover tax withholding obligations related to that award.

Were the CRL transactions in this Form 4 open-market buys or sells?

No, the transactions were a grant and tax-withholding dispositions. The filing classifies the 5,257 shares as a grant or award acquisition and the 979 shares as tax-withholding dispositions, meaning they were for compensation and tax purposes, not open-market trading decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:40 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaPlume Joseph W

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Corp Strategy & Develop

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		5,257(1)	A	$180.71	32,277	D
Common Stock	05/30/2026		F		744	D	$180.71	31,533	D
Common Stock	05/31/2026		F		235	D	$180.71	31,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Unvested restricted stock units annually ratably vest on: May 29, 2027; May 29, 2028; May 29, 2029; May 29, 2030.

	/s/ Joseph W. LaPlume	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)